FAIRplus logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
802750

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
3 996 150
EFPIA in kind
4 232 500
Total Cost
8 228 650

Summary

The vast amounts of data generated in life science research have the potential to add to our understanding of disease and help advance drug development. Yet most data is hidden away in proprietary databases and stored in different formats. The goal of FAIRplus is to deliver guidelines and tools to facilitate the application of ‘FAIR’ principles to data from certain IMI projects and datasets from pharmaceutical companies. FAIR stands for ‘findable, accessible, interoperable, reusable’. The project will therefore make it easier for other researchers to find the data and integrate it into their own research. The project will also organise training courses for data scientists in academia, small and medium-sized enterprises (SMEs) and pharmaceutical companies. Ultimately, the project hopes to change the culture of data management in the life sciences sector.

Achievements & News

The story so FAIR
May 2020

Making data FAIR (findable, accessible, interoperable and reusable) could supercharge medicine development. IMI’s FAIRplus project is putting the principles into practice. One of its main goals is to ‘FAIRify’ data from at least 20 IMI projects, as well as internal datasets from EFPIA companies. It has already selected or identified datasets from 13 projects.###

The project has also issued the first version of the FAIR Cookbook, an open-source collection of instructions (or ‘recipes’) for making life science data FAIR. The Cookbook shows users how to FAIRify datasets and put the FAIR principles into practice, and teaches users about levels and indicators of FAIRness; and the technologies and tools available to assess and improve FAIRness. The FAIR Cookbook is open source and anyone is invited to contribute.

Finally, the project has launched a programme in FAIR data management that will start in April 2021. Lasting 8 months, the FAIRplus Fellowship Programme will guide participants through a series of modules combining online learning, 'training on the job' and short face-to-face meetings. After completing the programme, people will have the confidence to lead, advise and initiate FAIR data processes in their own companies and organisations. Most fellows will be selected from among the FAIRplus partner organisations, but some spaces are reserved for applicants from outside the project. Although registration is not yet open, people can register their interest in the programme via an online form.

Find out more

Join the first FAIRplus Innovation and SME Forum
October 2019

IMI’s FAIRplus project will hold the first FAIRplus Innovation and SME Forum on 29 January 2020 in Hinxton, UK, to discuss the challenges and opportunities for large companies and SMEs in adopting FAIR data practices.### FAIR stands for ‘findable, accessible, interoperable, and reusable’. The goal of FAIRplus is to make it easier for researchers to find and access relevant data and integrate them into their own research. The project will deliver guidelines and tools to facilitate the application of FAIR principles to data from other IMI projects and pharmaceutical companies.

The FAIRplus Innovation and SME Forum is aimed at companies working with life science data, companies planning to provide FAIRification services and anyone interested in FAIRification of their data. The main goal of the event is to present the first outcomes of the project and hear from companies providing FAIR data solutions about their experience. The participants will also learn about the FAIRplus Fellowship programme which offers comprehensive FAIR data training, including a short stay at one of FAIRplus consortium partners.

Participation is free of charge, but registration is required.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Barcelona Supercomputing Center - Centro Nacional De Supercomputacion, Barcelona, Spain
  • European Molecular Biology Laboratory, Heidelberg, Germany
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain
  • Heriot-Watt University, Edinburgh, United Kingdom
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The University Of Manchester, Manchester, United Kingdom
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • Universite Paul Sabatier Toulouse Iii, Toulouse, France
  • Universiteit Maastricht, Maastricht, Netherlands
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Open Phacts Foundation Lbg, Cambridge, United Kingdom
  • Stichting Lygature, Utrecht, Netherlands
  • The Hyve BV, Utrecht, Netherlands
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
Project coordinator
Serena Scollen
European Molecular Biology Laboratory